Cisplatin combined with Etoposide
Small molecule
Cisplatin combined with Etoposide is one of 39 small molecule programs targeting Glioblastoma. It is currently in development.
1
Indications
1
Total Trials
1
Active Trials
38
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
514 competitors in Glioblastoma
#DrugCompanyPhaseTrials
1Temodar
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Ceenu
AAzurity Pharmaceuticals
Phase 3
Gleevec
NovartisPhase 3
Cymbalta
Alnylam PharmaceuticalsPhase 3
Scemblix
NovartisPhase 3
Lexapro
AbbViePhase 3
Zejula
GGlaxo Dba Glaxosmithkline
Phase 3
Feraheme
AAzurity Pharmaceuticals
Phase 3
Sprycel
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Droxia
TTheravia
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Glioblastoma1 trial
A Study of PLB1001 Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusion Gene (FUGEN).
Active, not recruiting·BBeijing Pearl Biotechnology Limited Liability Company·Phase 2/3·NCT06105619·84 enrolled
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]